Loading stock…

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

600196Market cap $8.77BPrice $3.5

Country🇨🇳China

SectorHealthcare

IndustryPharmaceuticals

Develops, manufactures, and sells pharmaceuticals, medical devices, and diagnostics across China and beyond. It even co-developed China's first mRNA COVID vaccine with BioNTech, making it one of the country's most diversified healthcare conglomerates.

In Bastion Portfolios?

52W Return-12%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-2%2

Revenue Forecast

Rev CAGR (1y)+7%5

Rev CAGR (3y)+4%3

Rev CAGR (5y)+11%8

Earnings Forecast

EPS Growth Y+1+17%8

EPS Growth Y+2-19%2

EPS Growth Y+3+28%8

Quality

Margins

EBIT Margin6%3

Net Income Margin8%5

Free Cash Flow Margin2%3

Debt

Net Debt/EBITDA3.72

Efficiency

ROE7%3

ROA4%5

Earnings Stability44

GEAR+WEAK29

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)185

P/E Ratio (Forward 3y)164

P/BV1.29

EV Multiples

EV/EBITDA Fwd106

EV/EBIT Fwd233

Yield

Free Cash Flow Yield1.2%3

Dividend Yield1.6%4

Momentum

Short term

1 month return+6%9

3 month return+6%8

YTD return-8%4

Mid term

Price vs 52wHigh80%5

1 year return-18%3

Long term

3 year return-13%2

5 year return-50%1

Risk Shield

Price Risk

Beta0.39

Volatility26%8

Free Cash Flow

Free Cash Flow Margin2%3

Free Cash Flow Yield1.2%3

Quality

ROCE3%2

Earnings Stability44

Net Debt/EBITDA3.72

02Growth

Is it actually growing, and how fast?

600196Shanghai Fosun Pharmaceutical (Group) Co.

Revenue FY25$6.0B

GROWTH RATING↗

AVERAGE42 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-2%2

Revenue, next 1Y+7%5

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+11%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+17%8

EPS growth, FY27E-19%2

EPS growth, FY28E+28%8

GROWTH ASSESSMENT

STRENGTHS

The runway holds up: revenue is set to grow 11%/yr over five years.8/10

WATCH

A mid-pack grower, ahead of 42% of companies worldwide.

Revenue is set to grow 4%/yr over the next 3 years, in line with the market.5/10

After shrinking over the last 3 years, revenue is set to grow 4%/yr from here.

Earnings are set to grow faster than sales (EPS about 17%/yr vs revenue 4%/yr), so margins should widen. One year dips: EPS falls 19% in year 2.

WEAKNESSES

Revenue fell 2%/yr over the last 3 years, behind 80% of companies worldwide.2/10

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

600196Shanghai Fosun Pharmaceutical (Group) Co.

Total return Current18.5%

Price return Current6.5%

MOMENTUM RATING↗

AVERAGE37 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+6%9

3-month return+6%8

YTD return-8%4

MID & LONG-TERM▾SCORE

% of 52-week high80%5

1-year return-18%3

3-year return-13%2

5-year return-50%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+6%) and over three months (+6%).

WATCH

It's down 18% over the past year, now 20% below its 52-week high. That is a touch behind the market.

Returns sit at the market level so far this year (-8%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-13% over three years and -50% over five), behind 80% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Shanghai Fosun Pharmaceutical (Group) Co., Ltd.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

600196Shanghai Fosun Pharmaceutical (Group) Co.

Revenue FY25$6.0B

GROWTH RATING↗

AVERAGE42 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-2%2

Revenue, next 1Y+7%5

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+11%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+17%8

EPS growth, FY27E-19%2

EPS growth, FY28E+28%8

GROWTH ASSESSMENT

STRENGTHS

The runway holds up: revenue is set to grow 11%/yr over five years.8/10

WATCH

A mid-pack grower, ahead of 42% of companies worldwide.

Revenue is set to grow 4%/yr over the next 3 years, in line with the market.5/10

After shrinking over the last 3 years, revenue is set to grow 4%/yr from here.

Earnings are set to grow faster than sales (EPS about 17%/yr vs revenue 4%/yr), so margins should widen. One year dips: EPS falls 19% in year 2.

WEAKNESSES

Revenue fell 2%/yr over the last 3 years, behind 80% of companies worldwide.2/10

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

600196Shanghai Fosun Pharmaceutical (Group) Co.

Total return Current18.5%

Price return Current6.5%

MOMENTUM RATING↗

AVERAGE37 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+6%9

3-month return+6%8

YTD return-8%4

MID & LONG-TERM▾SCORE

% of 52-week high80%5

1-year return-18%3

3-year return-13%2

5-year return-50%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+6%) and over three months (+6%).

WATCH

It's down 18% over the past year, now 20% below its 52-week high. That is a touch behind the market.

Returns sit at the market level so far this year (-8%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-13% over three years and -50% over five), behind 80% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Shanghai Fosun Pharmaceutical (Group) Co., Ltd.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community